Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


ThromboGenics prepares a potential listing on Euronext Brussels

Leuven, Belgium - 02 June, 2006 – ThromboGenics, a biopharmaceutical company focused on the development of novel medicines for the treatment of vascular disease announced today that it is considering an initial public offering in Brussels on Eurolist by Euronext.

ThromboGenics was founded in 1991 by Professor Désiré Collen, a world-renowned expert in cardiovascular disease, and KULeuven. Prof. Collen’s laboratory was the first to produce tissue plasminogen activator (tPA) for clinical use. tPA, which is marketed by the U.S. biotechnology company Genentech, is the most successful thrombolytic agent (by sales) for the treatment of heart attacks. Prof. Collen founded ThromboGenics to use the expertise gained with tPA to develop superior vascular therapeutics.

ThromboGenics has developed a significant pipeline of drug candidates for the treatment of a broad range of conditions related to the vascular system, including visual disorders, cardiovascular diseases and cancer. The Company has five programs in clinical development including microplasmin, a proteolytic enzyme which is being evaluated as a treatment for important back of the eye disorders such as macular edema and diabetic retinopathy. Microplasmin is also being developed as a thrombolytic agent for acute stroke and peripheral vascular disease.

ThromboGenics also has five other drug candidates in preclinical development with preclinical proof of principle demonstrated, including TB-403 (Anti-PlGF) and TB-402 (Anti-Factor VIII).

ThromboGenics intends to use the net proceeds from the offering to advance its clinical and preclinical therapeutic pipeline and to in-license new drug candidates, should the opportunity arise.

In connection with the proposed IPO, KBC Securities has been appointed Lead Manager, Nomura Code Co-Lead Manager.

The IPO and listing are expected to complete in the next few months, subject to obtaining the approval of the Belgian Banking, Finance and Insurance Commission (BFIC). Further details of the proposed offering will be announced at a later date.

About ThromboGenics
ThromboGenics is a privately held company headquartered in Leuven, Belgium focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for acute stroke and peripheral arterial occlusive disease. ThromboGenics also has five other drug candidates in preclinical development with preclinical proof-of-principle demonstrated, including TB-402 (Anti-Factor VIII) and TB-403 (Anti-PlGF). The Company has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics has subsidiaries in Ireland and the U.S. More information is available at

Publisher Contact Information:

ThromboGenics Ltd.
+32 (0)16 34 61 94

Company profile of ThromboGenics Ltd.
Past press releases of ThromboGenics Ltd. .


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.